NEW YORK (GenomeWeb News) – Toronto-based Spectral Diagnostics said today it will provide Bio-Rad Pasteur with single chain Troponin I reagents under a license and supply agreement.
 
Spectral CEO Paul Walker said the “consistent revenue stream” from the agreement will generate capital the company needs to commercialize its FDA-approved endotoxemia assay, which also tests for the subsequent risk of sepsis.
 
Financial terms of the agreement were not released.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.